BioVantra
  • Home
  • About
  • Services04
    01 Integrated Prostate Cytomolecular Testing Integrated cytologic and molecular information in a structured, clinically useful report. 02 Prostate Cancer Estimation and Mapping Structured interpretation of cancer extent, lesion distribution, and treatment relevance. 03 Integrated Urothelial Cytomolecular Testing Non-invasive cytology and molecular analysis to support bladder cancer detection and surveillance. 04 Digital Pathology and Reporting Support Digital pathology and synoptic reporting support for clarity and consistency.
    Full service catalogue View all services →
  • Resources
  • Contact
Client Portal Request Information →
  • Home
  • About
    • All services
    • Diagnostic services
    • Integrated Prostate Cytomolecular Testing
    • Integrated Urothelial Cytomolecular Testing
    • Prostate Cancer Estimation and Mapping
    • Digital Pathology and Reporting Support
  • Resources
  • Contact
Client Portal Request Information →
Legal · Electronic Communications

Electronic Communications Policy

This policy describes the channels available for communicating with BioVantra, the limitations of each channel, and how to communicate appropriately about protected health information (PHI).

Effective: May 11, 2026 · Last updated: May 11, 2026

Do not send PHI through unencrypted email or through this public website. Standard email is not encrypted in transit or at rest and is not an appropriate channel for protected health information. PHI-related communications with BioVantra should be made through the Lumea BxLink Client Portal, by phone, by fax, or by another secure method arranged with our team.

1. Communication channels

  • Email (general inquiries): contact@biovantra.com — for non-PHI inquiries, including questions about services, workflow fit, onboarding, and general client support.
  • Phone: (352) 861-2296 — direct line during standard business hours, Monday through Friday.
  • Fax: (352) 671-2737 — when requested as part of an established clinical or operational workflow.
  • Lumea BxLink Client Portal: bxlink.lumea.net — used by clients to access diagnostic reports, case history, and related clinical workflow information.
  • Mail: BioVantra, 9401 SW Highway 200, STE 502, Ocala, FL 34481-9650 — for correspondence and shipments.

2. Appropriate use of email

Unencrypted email — including email sent to contact@biovantra.com — is suitable for general, non-PHI communication. By sending email to BioVantra, you acknowledge that standard email is not a secure channel and accept the inherent risks of transmitting non-sensitive information by this method. Do not include patient names, dates of birth, identifiers, clinical details, images, scans, reports, or any other PHI in email to BioVantra.

If BioVantra inadvertently receives PHI through unencrypted email, BioVantra will take reasonable steps to safeguard or remove the information consistent with its internal policies and applicable law.

3. Lumea BxLink Client Portal

The Lumea BxLink Client Portal is the primary channel for client-facing exchange of diagnostic reports, case history, and related clinical workflow information. Access is provided to authorized client users under separate terms with the portal operator. BioVantra does not control the portal's technical environment but selects it as part of its clinical workflow because it is designed for clinical information exchange. If you do not have portal access or are experiencing access issues, contact BioVantra using the channels above.

4. Phone and fax

Phone is suitable for direct conversation about practice setup, onboarding, scheduling, and general inquiries. PHI communicated by phone is handled by BioVantra personnel under standard confidentiality and HIPAA-aware practices. Fax is used when expressly requested by an established workflow; clients are responsible for confirming the destination fax number before transmitting any sensitive information.

5. No public contact form

biovantra.com does not currently include a public contact form. All web-initiated communication is directed to standard channels (email, phone, fax, or the Lumea BxLink Client Portal). This is an intentional choice to reduce the risk of inadvertent PHI submission through the public site. If a contact form is introduced in the future, this policy will be updated and the form will include explicit no-PHI notice.

6. Response times

BioVantra responds to inquiries during standard business hours, Monday through Friday. Response time may vary depending on the nature of the inquiry, current case volume, and whether the message is appropriately routed. Inquiries received outside business hours will be reviewed on the next business day.

7. Emergencies

Email, phone messages, fax, and the Lumea BxLink Client Portal are not appropriate channels for clinical emergencies. If you are experiencing a medical emergency, call 911 or your local emergency number, or go to the nearest emergency department.

8. Consent and changes

By initiating electronic communication with BioVantra through the channels described above, you consent to the corresponding form of communication as described in this policy. BioVantra may update this policy from time to time. Material changes will be reflected by an updated "Last updated" date at the top of this page.

9. Contact

Questions about this policy can be sent to contact@biovantra.com.

BioVantra

Integrated urologic diagnostics — cytomolecular testing, cancer estimation and mapping, and digital pathology and reporting support for urologists and other healthcare professionals involved in the diagnosis, surveillance, and treatment planning of prostate and bladder cancer.

Company
Home About Contact
Services
Integrated Prostate Cytomolecular Testing Prostate Cancer Estimation & Mapping Integrated Urothelial Cytomolecular Testing Digital Pathology & Reporting Support
For clients
Resources Client Portal Support / Contact
Email contact@biovantra.com
Phone (352) 861-2296 Fax (352) 671-2737
Office 9401 SW Highway 200, STE 502
Ocala, FL 34481-9650
Quality CAP Accredited · 7214934 CLIA Certified · 10D1087213
© 2026 BioVantra. All rights reserved.
Privacy Terms HIPAA Notice Disclaimer Electronic Communications Accessibility Nondiscrimination